Reconfiguring COVID and influenza vaccines for long-term effectiveness
pharmaphorum
SEPTEMBER 22, 2022
What makes us special is that we have this technology platform that allows us to target the internal parts of a virus. However, a vaccine trains the immune system to recognise that familiar virus and kill it more rapidly. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.
Let's personalize your content